Navigation Links
3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
Date:11/24/2008

SHENYANG, China, Nov. 24 /PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced that Dr. Yingfei Wei, Chief Scientific Officer, will present at the Piper Jaffray 20th Annual Health Care Conference in New York on Tuesday, December 2, 2008 at 11:00AM (Eastern Time).

The presentation will be webcast live (audio only) and can be accessed on the Conference Appearances section of the Investors page of the 3SBio website at: http://bbs.3sbio.com/en/News/ShowInfo_nnn6.aspx?ID=65 . A replay of the presentation and accompanying slides will be available on the 3SBio website until January 1, 2008.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China.

For more information, please visit 3SBio on the web at: http://www.3sbio.com .

    For further information, please contact:

    Investor Contact:
     David Chen, COO
     3SBio Inc.
     Email: ir@3sbio.com

    Investor Relations (US):
     Mahmoud Siddig
     Taylor Rafferty
     Tel: +1-212-889-4350

    Investor Relations (HK):
     Ruby Yim
     Taylor Rafferty
     Tel: +852-3196-3712

    Media Contact:
     Jason Marshall
     Taylor Rafferty
     Tel: +1-212-889-4350

'/>"/>
SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. 3SBio Inc. Announces Third Quarter 2008 Results
2. 3SBio Inc. Files for SFDA Approval of NuLeusin
3. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
4. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
5. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
6. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
7. 3SBio Inc. Announces Results of Annual General Meeting
8. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. 3SBio Inc. to Hold Annual General Meeting
10. 3SBio Inc. Announces Second Quarter 2008 Results
11. 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017  Spherix Incorporated (Nasdaq: ... committed to the fostering of technology and monetization of ... patent infringement lawsuits. Anthony Hayes , ... 2017, we will continue to communicate with shareholders about ... and our due diligence on other patent assets that ...
(Date:1/23/2017)... CARLOS, Calif. , Jan. 23, 2017 /PRNewswire/ ... developing innovative treatments for neurodegenerative diseases and other ... has joined the company as Chief Medical Officer. ... translational and clinical development activities at Alkahest and ... Dr. Jackson most recently served as Executive Director ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... our ongoing endeavors to bring to market a pioneering medical device for the ... has signed an engagement contract with Emergo, a global regulatory consultancy that helps ...
(Date:1/20/2017)... ... ... The two newest companies to join the University City Science Center’s Port business ... Wistar Institute, and Sanguis, launched by a trio of students from the University of ... developing a treatment for a chronic viral infection and its associated diseases, with the ...
Breaking Biology Technology:
(Date:12/20/2016)... Dec. 20, 2016 The rising popularity ... and leasing is stoking significant interest in keyless ... technology, Bluetooth low energy (BLE), biometrics and near-field ... next wave of wireless technologies in the automotive ... to advanced access systems opens the market to ...
(Date:12/19/2016)... , España y TORONTO , 19 de ... con Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, ... clínicos en varios tipos de tumor en 2017, con múltiples sitios ... ... su clase con objetivo en el factor inhibidor de leucemia (LIF), ...
(Date:12/16/2016)... Dec 16, 2016 Research and Markets has ... - Global Forecast to 2021" report to their offering. ... The biometric vehicle ... at a CAGR of 14.06% from 2016 to 2021. The market ... projected to reach 854.8 Million by 2021. The growth of the ...
Breaking Biology News(10 mins):